Bactiguard Holding AB (publ) (BACTI_B) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, Operator, and welcome to the presentation of Back to Guard's report for the second quarter 2025. Our CFO, Patrick Buck, and I will go through the presentation together, and we will have a Q&A session towards the end. As usual, I would like to share some highlights from the past quarter, and Patrick will go through the figures in more detail later in the presentation. First, we continue to deliver EBITDA profitability with this quarter totaling 4.4 million SEC. This is the fifth consecutive quarter with positive EBITDA for BactaGard in alignment with our promise to our investors during our strategic transformation. Revenues for Q2 came in at 52.1 million SEC, which was a decrease of 14.4% compared to last year. This is mainly explained by lower revenues from the BD partnership due to longer than expected timelines for new market registrations, as well as negative US dollar currency impact. Nevertheless, our collaboration with BD remains solid, and I will elaborate on this later in the presentation. We have also initiated early feasibility work relevant to cardiology under material transfer agreement. Cardiology is one of our newer key strategic therapeutic areas announced in the first quarter, and the applications for future potential licensing hold meaningful value. Our wound management portfolio had revenues of almost 14 million SEC. slightly lower than Q2 last year due to the slower sales of our suture products, but offset by strong growth in Hydrosyn Aqua. Our Hydrosyn brand now represents the majority of the revenues in the wound management portfolio. And notably, over the first six months of 2025, the total wound management portfolio delivered 21% growth compared to last year. As I stated in the CEO letter, infection prevention is our mission. It rema...